This $131,220 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support cancer vaccine research under the Cancer Research Manpower federal grant program (CFDA 93.398).
The grant recipient, Stanford University, will develop a new approach to cancer vaccination that directly reprograms cancer cells into antigen presenting cells (APCs) through mRNA-enabled cell reprogramming. Researchers aim to overcome barriers to current vaccination methods by engineering APCs that exhibit cancer-derived antigens and proper costimulatory molecules for efficient T cell activation. Specifically, the project involves developing gene delivery vehicles for cancer cell reprogramming, elucidating relationships between vehicle structure and function, and evaluating reprogrammed APCs for their ability to elicit an anti-tumor immune response and immunological memory in cell lines and animal models. Findings seek to lay the groundwork for future clinical application of this cell reprogramming technology and contribute to the fields of gene delivery, immunotherapy, and cancer vaccine development.
Generated 1/7/24, 1:23 AM